James Hardiman

James Hardiman is an accomplished investor and board member with extensive experience in the biotechnology and technology sectors. Currently serving as an Investor and Board Observer at Recursion Pharmaceuticals, NOETIK, Amogy, Q-CTRL, and Gro Intelligence, and as a Board Director at NOETIK, Shennon Biotechnologies, Lumafield, and Gradle Inc., Hardiman focuses on innovative solutions in precision immunotherapy, sustainable energy, and advanced software development. Educational credentials include a Bachelor of Science in Engineering Physics from the University of California, Berkeley, and a Master of Business Administration from The University of Chicago Booth School of Business.